
Home » Debiopharm, Ascenta ink exclusive license agreement
Debiopharm, Ascenta ink exclusive license agreement
September 7, 2011
Debiopharm Group and Ascenta Therapeutics have entered into an exclusive worldwide license agreement concerning the development and commercialization of AT-406 (called Debio 1143 by Debiopharm) a small molecule IAP inhibitor currently in phase I development. By targeting inhibitors of apoptosis proteins, AT-406 (or Debio 1143) can induce cancer cell death and/or potentiate the efficacy of other treatments and is expected to be effective in the treatment of various cancers in combination with anti-cancer therapies.
"We are very excited about this collaboration with Ascenta Therapeutics. This company has an impressive scientific team and expertise in the field of apoptosis", said Dr. Rolland-Yves Mauvernay, president and founder of Debiopharm. He continued, "it should be possible to combine AT-406 (or Debio 1143) with other pro-apoptotic agents, which can potentially bring huge benefits to patients by enhancing the efficiency of the treatment."
Upcoming Events
-
25Apr
-
26Apr
-
27Apr
-
17May
-
21May